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Abstract: The SAPHO syndrome represents a variety of clinically similar disorders with the key features of hyperostotic 
bone lesions in combination with chronic pustular skin disease. The respective pathophysiology of bone and joint mani-
festations in SAPHO syndrome is still a matter of discussion. For example it does not appear to represent reactive arthritis 
and HLA B27 antigen, with the latter being typically present in patients with spondyloarthopathies. Treatment of SAPHO 
syndrome is also not well established and consists of various antiinflammatory and antirheumatic drugs. Here, we report a 
female patient with active SAPHO syndrome suffering from sternal swelling of unknown origin that had been known for 
10 years and a 4-year-history of severe lower back pain. Remarkable were also a typical pustulous palmar erythema asso-
ciated with swelling and decreased motility of both MCP-I joints. Inflammation parameters were high with an ESR 68 
mm/1st hour and a CRP of 19.6 mg/l. She was initially treated with rofecoxib and doxycycline, followed by sulfasalazine 
with only partial clinical response. Thereafter, both articular symptoms as well as cutaneous lesions responded well to a 
combination therapy with methotrexate and sulfasalazine. Thus, the case illustrates nicely that methotrexate in combina-
tion with another DMARD can be successfully applied to patients with long-term active SAPHO syndrome. 
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INTRODUCTION 
  The SAPHO syndrome represents a variety of clinically 
similar disorders with the key features of hyperostotic bone 
lesions, frequently seen on the anterior chest wall, in combi-
nation with chronic pustular skin disease [1]. The acronym 
SAPHO (for synovitis, acne, pustulosis, hyperostosis, and 
osteitis) was proposed by Chamot et al. after a national sur-
vey carried out in France 1986 to evaluate the range of skin, 
bone and joint manifestations observed. At present, there are 
over 450 published cases of SAPHO syndrome. 
  The pathogenesis and pathophysiology of bone and joint 
manifestations in SAPHO syndrome remain controversial. 
They do not appear to represent reactive arthritis and HLA 
B27 antigen, which is typically present in patients with 
spondyloarthropathies, and is usually lacking. However, in 
clinical practice, SAPHO syndrome has been associated with 
spondyloarthropathies, especially in those cases showing 
sacroiliac involvement and enthesiopathies. Sonozaki et al. 
have proposed diagnostic criteria for the SAPHO syndrome: 
pustulosis palmaris et plantaris, tenderness and swelling of  
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the sternocostoclavicular region, or in the absence of swel-
ling, the presence of radiologic signs of hyperostosis [2]. 
Technetium bone scintigrams and computed tomographs are 
considered the most important diagnostic tests. Due to the 
low number of patients, treatment of SAPHO syndrome is 
poorly established, it consists usually of antiinflammatory 
agents such as NSAIDs, and corticosteroids for more severe 
forms [3]. Case reports have also reported the use of various 
DMARDs with conflicting results [4]. 
CASE 
  A 63-year-old woman was referred to our hospital for 
evaluation of a sternal swelling of unknown origin that had 
been known for 10 years. In addition, she had a 4-year-history 
of severe lower back pain. At time of admission, she com-
plained about chronic pain in the lower back and in both meta-
carpophalangeal (MCP) I joints. She further reported episodes 
of loose stools and “allergies” to nonsteroidal antirheumatic 
drugs. Examination showed a tender swelling of her right 
sternoclavicular joint and a reduced motility of the complete 
vertebral column. A pustulous palmar erythema (Fig. 1a) 
associated with swelling and decreased motility of both MCP-
I joints was remarkable. Erythrocyte sedimentation rate was 
68 mm/1st hour, the C reactive protein concentration was 19.6 
mg/l (< 5). Immunoglobulins A and E were elevated, all other 
rheumatologic parameters including rheumatoid factor were 
within the normal range or negative. Conventional X-Rays 
and computed tomographs showed sternal hyperostotic re-Combination Therapy for SAPHO Syndrome  The Open Rheumatology Journal, 2009, Volume 3    19 
gions with a ventrodorsal diameter of 3 cm and a transversal 
diameter of 4 cm (Fig. 2a). Bone scintigrams demonstrated 
multiple enhanced signal intensities that were consistent with 
pustulotic arthroosteitis (Fig. 2b). A dermatology referral 
confirmed that the skin eruptions on palms and hands were a 
manifestation of SAPHO syndrome. The clinical picture com-
bining hyperostosis of the sternum with palmoplantar pustulo-
sis and spondylitis fulfilled the diagnostic criteria for SAPHO 
syndrome as outlined above. In addition, colonoscopy re-
vealed aphthous lesions in the ileum with histological signs of 
chronic inflammation. 
(a) 
 
(b) 
 
Fig. (1). (a) Typical pustulous palmar eruptions at the time of initial 
presentation (). (b) Presentation after 6 weeks doxycyline/8 weeks 
sulfasalazine therapy (). 
  There are several reports about a possible infectious 
etiology of the SAPHO syndrome. Edlund and coworkers 
reported isolation of Propionibacterium acnes, a Gram-
positive rod, in a series in 7 of 15 patients from patients with 
SAPHO syndrome [5] and Ballare et al. have reported a 
sustained response to doxycycline therapy in two patients 
with SAPHO syndrome [6]. Therefore, we decided to start a 
combination therapy consisting of rofecoxib 12.5 mg daily 
with doxycycline 100 mg bid although skin cultures of the 
palmoplantar lesions were negative for bacteria. Sulfasa-
lazine is recommended for the therapy of many HLA B27 
antigen-negative and -positive spondylarthropathies and has 
shown good results for SAPHO syndrome in uncontrolled 
reports [7]. Although sulfasalazine as a therapeutic agent in  
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Fig. (2). (a) Axial CT scan of the sternal region reveals marked 
hyperostosis and osteitis of the sternum (). (b) Technetium-99m 
bone scintigram shows considerable activity in the sternoclavicular, 
sternocostal joints and the vertebral column (). (c) After 26 
months of therapy, overall signal intensities have decreased sub-
stantially in the sternal region (). 
SAPHO syndrome has not been evaluated in controlled 
clinical trials and as other reports link SAPHO syndrome 
with chronic inflammatory bowel disease [8, 9], we added 
sulfasalazine with an initial dose of 500 mg twice a day to 
the patient’s medication. 
  The patient was discharged and followed on a regular 
basis in our outpatient rheumatology clinic for two and a half 
years. The course of disease and treatment are summarized 
in Fig. (3). The initial treatment with doxycycline had to be  20    The Open Rheumatology Journal, 2009, Volume 3  Huber et al. 
discontinued after 6 weeks due to oral aphthous lesions and 
the dose of sulfasalazine was increased to a total daily dose 
of 4.5 g. Over 8 weeks, the back and joint improved mark-
edly, skin eruptions disappeared completely (Fig. 1b) and the 
erythrocyte sedimentation rate (ESR) returned to 32/1
st hour. 
After 6 months under this therapy, bone scintigrams also 
improved markedly (Fig. 2c). A clinical and scintigraphic 
relapse occurred when the patient stopped taking her medica-
tion for a three month period between clinical visits. Symp-
toms ameliorated after starting again with sulfasalazine (Fig. 
3). After 19 months, due to increased activity, methotrexate 
(MTX) was added to the above regimen at a dose of 15 mg 
weekly (in combination with folate) and sulfasalazine was 
reduced to 500 mg three times a day. For the next three 
years, back pain was dramatically reduced, with the excep-
tions of a flare-up during a urinary tract infection and a mild 
viral respiratory tract infection. The remaining pain in both 
MCP-I joints resolved after carpal tunnel surgery. 
DISCUSSION 
  The hallmark of SAPHO syndrome is an inflammatory 
polytopic arthroosteits, which is characteristically sterile, 
although infectious agents are suspected as trigger [5, 6].   
 
There are several reports about a possible infectious etiology 
of the SAPHO syndrome. Edlund and coworkers reported 
isolation of Propionibacterium acnes, a Gram-positive rod, 
in a series in 7 of 15 patients from patients with SAPHO 
syndrome [7] and Ballare et al. have reported a sustained 
response to doxycycline therapy in two patients with SA-
PHO syndrome [8]. The present case demonstrates that com-
bination therapy with an antibiotic and a spondyloarthropa-
thy-approved disease-modifying drug (DMARD), e.g. doxy-
cycline and sulfasalazine, may be a successful approach for 
the initial therapy of this disease entity. Owing to the rare 
nature of SAPHO syndrome, sulfasalazine has not yet been 
evaluated in controlled clinical trials as a therapeutic agent. 
Nevertheless, Sulfasalazine is recommended for the therapy 
of many HLA B27 antigen-negative and -positive spondy-
larthropathies. Other reports link SAPHO syndrome with 
chronic inflammatory bowel disease [9, 10], and have shown 
good results for SAPHO syndrome in uncontrolled reports 
[11]. Consistent with promising data of Cabay and cowork-
ers, who reported rapid improvement in a patient with pustu-
losis plantaris and hyperostosis of the lumbar spine after two 
months of therapy with MTX (7.5 mg weekly) [12], MTX 
facilitated in our case the reduction of the dose of sulfasa-
lazine in a similar manner in long term therapy. 
 
 
Fig. (3). Overview over treatment and disease activity. ESR values (1
st hour) and concurrent therapy are shown for a 31-month-period. 
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